Outcomes of opioid-dependence treatment across Europe: Identifying opportunities for improvement

Heroin Addiction and Related Clinical Problems

Volumn 14, Issue 4, 2012, Pages 39-50

  Fischer, Gabriele ^a   Nava, Felice ^b   Stöver, Heino ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Sports Medicine Unit   (Italy)

^c FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Diversion; Illicit drug use; Misuse; Treatment cycling

Indexed keywords

ARTICLE; DRUG MISUSE; EUROPE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SELF REPORT;

EID: 84871631197     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. AKZEPT E.V. IN KOOPERATION MI T DER DEUTSCHEN GESELLSCHAFT FÜR SUCHTMEDI Z IN (DGS) UND DE M BERUFSVERBAND DEUTSCHER PSYCHIATER / DEUTSCHER NERVENÄRZTE. (2011): Substitution und Psychotherapie im stationären und ambulanten Setting. Last accessed 29 October 2012 at www.akzept.org.
2. AMATO L., MINOZZI S., DAVOLI M., VECCHI S. (2011): Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev: CD004147.
3. BACHA J., REAST S., PEARLSTONE A. (2010): Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl 12: 9-19.
4. DUFFY P., BALDWIN H. (2012): The nature of methadone diversion in England: a Merseyside case study. Harm Reduct J 9: 3.
5. EMCDDA. (2010): Harm reduction: evidence, impacts and challenges. Last accessed 29 March 2012 at www.emcdda.europa.eu.
6. FISCHER G., STÖVER H. (2012): Assessing the current state of opioid-dependence treatment across Europe: methodology of the European Quality Audit of Opioid Treatment (EQUATOR) project. Heroin Addict Relat Clin Probl 14: 5-70.
7. GIACOMUZZI S.M., RIEMER Y., ERTL M., KEMMLER G., ROSSLER H., HINTERHUBER H., KURZ M. (2003): Buprenorphine versus methadone maintenance treatment in an ambulant setting: a healthrelated quality of life assessment. Addiction 98: 693-702.
8. GOWING L.R., FARRELL M., BORNEMANN R., SULLIVAN L.E., ALI R.L. (2006): Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 21: 193-195.
9. GRANT B.F., STINSON F.S., DAWSON D.A., CHOU S.P., DUFOUR M.C., COMPTON W., PICKERING R.P., KAPLAN K. (2004): Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61: 807-816.
10. GRONBLADH L., OHLUND L.S., GUNNE L.M. (1990): Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand 82: 223-227.
11. MATTICK R.P., ALI R., WHITE J.M., O'BRIEN S., WOLK S., DANZ C. (2003): Buprenorphine versus methadone maintenance therapy: a randomized doubleblind trial with 405 opioid-dependent patients. Addiction 98: 441-452.
12. MATTICK R.P., BREEN C., KIMBER J., DAVOLI M. (2009): Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev: CD002209.
13. MATTICK R.P., KIMBER J., BREEN C., DAVOLI M. (2008): Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev: CD002207.
14. MCLELLAN A.T., CHALK M., BARTLETT J. (2007): Outcomes, performance, and quality: what's the difference? J Subst Abuse Treat 32: 331-340.
15. MCLELLAN A.T., LEWIS D.C., OBRIEN C.P., KLEBER H.D. (2000): Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284: 1689-1695.
16. MITCHELL T.B., WHITE J.M., SOMOGYI A.A., BOCHNER F. (2003): Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 72: 85-94.
17. NOSYK B., SUN H., EVANS E., MARSH D.C., ANGLIN M.D., HSER Y.I., ANIS A.H. (2012): Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction 107: 1621-1629.
18. ORMAN J.S., KEATING G.M. (2009): Buprenorphine/ naloxone: a review of its use in the treatment of opioid dependence. Drugs 69: 577-607.
19. REISSNER V., KOKKEVI A., SCHIFANO F., ROOM R., STORBJORK J., STOHLER R., DIFURIA L., REHM J., GEYER M., HOLSCHER F., SCHERBAUM N. (2012): Differences in drug consumption, comorbidity and health service use of opioid addicts across six European urban regions (TREAT-project). Eur Psychiatry 27: 455-462.
20. ROOK E.J., HUITEMA A.D., VAN DEN BRINK W., VAN REE J.M., BEIJNEN J.H. (2006): Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1: 109-118.
21. VIRK M.S., ARTTAMANGKUL S., BIRDSONG W.T., WILLIAMS J.T. (2009): Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci 29: 7341-7348.
22. WALSH S.L., PRESTON K.L., STITZER M.L., CONE E.J., BIGELOW G.E. (1994): Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55: 569-580.
23. WORLD HEALTH ORGANIZATION. (2009): Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Last accessed 26 October 2012 at www.who.int.